{"id":76665,"date":"2026-08-26T12:51:26","date_gmt":"2026-08-26T04:51:26","guid":{"rendered":"https:\/\/flcube.com\/?p=76665"},"modified":"2026-08-26T12:51:27","modified_gmt":"2026-08-26T04:51:27","slug":"wuxi-biologics-2026h1-revenue-climbs-18-4-to-rmb-11-8-billion-as-project-pipeline-hits-1064-integrated-programs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76665","title":{"rendered":"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>WuXi Biologics (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2269:HKG\">HKG: 2269<\/a>)<\/strong> announced its interim results for the six months ended 30 June 2026, reporting <strong>revenue of RMB 11.8 billion, up 18.4% year\u2011on\u2011year<\/strong>, driven by strong demand for new IND projects, continuous progression of projects into late\u2011stage development, and growing commercial manufacturing programs. The company achieved <strong>positive free cash flow of RMB 1.5 billion<\/strong> in the first half \u2014 its <strong>fifth consecutive year<\/strong> of positive free cash flow in H1.<\/p>\n\n\n\n<h2 id=\"h-2026h1-financial-highlights\" class=\"wp-block-heading\">2026H1 Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026H1<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Revenue<\/strong><\/td><td>RMB 11.8B<\/td><td><strong>+18.4% YOY<\/strong><\/td><\/tr><tr><td><strong>Free Cash Flow<\/strong><\/td><td>RMB 1.5B<\/td><td>Positive for fifth consecutive year<\/td><\/tr><tr><td><strong>Integrated Projects Added<\/strong><\/td><td>169<\/td><td>123 organic (+43% YOY) + 46 via WuXi XDC&#8217;s acquisition of Tot Biopharm<\/td><\/tr><tr><td><strong>Total Integrated Projects<\/strong><\/td><td>1,064<\/td><td>As of 30 June 2026<\/td><\/tr><tr><td><strong>Phase III Projects<\/strong><\/td><td>78<\/td><td>Late\u2011stage pipeline expansion<\/td><\/tr><tr><td><strong>Commercial Manufacturing Projects<\/strong><\/td><td>28<\/td><td>Sustained commercial revenue growth<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-growth-drivers\" class=\"wp-block-heading\">Growth Drivers<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Organic Project Momentum:<\/strong> <strong>123 organically grown integrated projects<\/strong>, up <strong>43% YOY<\/strong>, with <strong>two\u2011thirds originating from the U.S. and Europe<\/strong> \u2014 highlighting strong demand from major pharmaceutical companies and biotech firms in key Western markets.<\/li>\n\n\n\n<li><strong>Inorganic Expansion:<\/strong> <strong>46 integrated projects<\/strong> added through <strong>WuXi XDC&#8217;s acquisition of Tot Biopharm<\/strong>, strengthening the Group&#8217;s capabilities in the rapidly growing XDC (antibody\u2011drug conjugate) segment.<\/li>\n\n\n\n<li><strong>Late\u2011Stage and Commercial Mix:<\/strong> The expansion to <strong>78 Phase III projects and 28 commercial manufacturing projects<\/strong> continues to shift the portfolio toward higher\u2011value, recurring\u2011revenue manufacturing \u2014 a structural tailwind for margins.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-research-business-amp-royalty-pipeline\" class=\"wp-block-heading\">Research Business &amp; Royalty Pipeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Milestone &amp; Royalty Eligible Projects:<\/strong> More than <strong>50 active projects<\/strong> eligible for milestone payments and sales royalties as of 30 June 2026, laying a foundation for long\u2011term, <strong>high\u2011margin revenue growth<\/strong>.<\/li>\n\n\n\n<li><strong>Global Client Base:<\/strong> Over <strong>50% of these projects<\/strong> came from clients outside of China, reflecting the continuous deepening of the Group&#8217;s global research services footprint.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Backlog Quality:<\/strong> The record <strong>1,064 integrated projects<\/strong> \u2014 with rising Phase III and commercial representation \u2014 provides strong visibility into future manufacturing revenue and reinforces WuXi Biologics&#8217; position as a leading global CDMO.<\/li>\n\n\n\n<li><strong>Geographic Diversification:<\/strong> With two\u2011thirds of new organic projects sourced from the U.S. and Europe, demand resilience from Western biopharma remains intact despite geopolitical scrutiny of China\u2011based CRDMOs.<\/li>\n\n\n\n<li><strong>Cash Generation:<\/strong> Five consecutive years of positive H1 free cash flow underscores the sustainability of the &#8220;follow\u2011the\u2011molecule&#8221; model as projects mature into commercial manufacturing.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding revenue growth, project progression, and commercial manufacturing expectations for WuXi Biologics. Actual results may differ due to risks including client demand, geopolitical developments, and project execution timelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082500945.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082500945.\"><\/object><a id=\"wp-block-file--media-421cc91f-7e4e-485a-9ec8-1ab91a8e83c6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082500945.pdf\">2026082500945<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082500945.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-421cc91f-7e4e-485a-9ec8-1ab91a8e83c6\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082501449.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082501449.\"><\/object><a id=\"wp-block-file--media-f39944f5-f61f-4b22-8e74-c5333d8a3b3e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082501449.pdf\">2026082501449<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082501449.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f39944f5-f61f-4b22-8e74-c5333d8a3b3e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76671,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,4908],"tags":[27,952,292],"class_list":["post-76665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-pic","tag-finanical-reports","tag-hkg-2269","tag-wuxi-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June 2026, reporting revenue of RMB 11.8 billion, up 18.4% year\u2011on\u2011year, driven by strong demand for new IND projects, continuous progression of projects into late\u2011stage development, and growing commercial manufacturing programs. The company achieved positive free cash flow of RMB 1.5 billion in the first half \u2014 its fifth consecutive year of positive free cash flow in H1.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76665\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs\" \/>\n<meta property=\"og:description\" content=\"WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June 2026, reporting revenue of RMB 11.8 billion, up 18.4% year\u2011on\u2011year, driven by strong demand for new IND projects, continuous progression of projects into late\u2011stage development, and growing commercial manufacturing programs. The company achieved positive free cash flow of RMB 1.5 billion in the first half \u2014 its fifth consecutive year of positive free cash flow in H1.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76665\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T04:51:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-26T04:51:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2605.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76665#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76665\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs\",\"datePublished\":\"2026-08-26T04:51:26+00:00\",\"dateModified\":\"2026-08-26T04:51:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76665\"},\"wordCount\":420,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76665#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2605.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 2269\",\"WuXi Biologics\"],\"articleSection\":[\"Company\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76665#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76665\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76665\",\"name\":\"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76665#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76665#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2605.webp\",\"datePublished\":\"2026-08-26T04:51:26+00:00\",\"dateModified\":\"2026-08-26T04:51:27+00:00\",\"description\":\"WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June 2026, reporting revenue of RMB 11.8 billion, up 18.4% year\u2011on\u2011year, driven by strong demand for new IND projects, continuous progression of projects into late\u2011stage development, and growing commercial manufacturing programs. The company achieved positive free cash flow of RMB 1.5 billion in the first half \u2014 its fifth consecutive year of positive free cash flow in H1.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76665#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76665\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76665#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2605.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2605.webp\",\"width\":1080,\"height\":608,\"caption\":\"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76665#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs - Insight, China&#039;s Pharmaceutical Industry","description":"WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June 2026, reporting revenue of RMB 11.8 billion, up 18.4% year\u2011on\u2011year, driven by strong demand for new IND projects, continuous progression of projects into late\u2011stage development, and growing commercial manufacturing programs. The company achieved positive free cash flow of RMB 1.5 billion in the first half \u2014 its fifth consecutive year of positive free cash flow in H1.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76665","og_locale":"en_US","og_type":"article","og_title":"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs","og_description":"WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June 2026, reporting revenue of RMB 11.8 billion, up 18.4% year\u2011on\u2011year, driven by strong demand for new IND projects, continuous progression of projects into late\u2011stage development, and growing commercial manufacturing programs. The company achieved positive free cash flow of RMB 1.5 billion in the first half \u2014 its fifth consecutive year of positive free cash flow in H1.","og_url":"https:\/\/flcube.com\/?p=76665","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-26T04:51:26+00:00","article_modified_time":"2026-08-26T04:51:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2605.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76665#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76665"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs","datePublished":"2026-08-26T04:51:26+00:00","dateModified":"2026-08-26T04:51:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76665"},"wordCount":420,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76665#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2605.webp","keywords":["Finanical Reports","HKG: 2269","WuXi Biologics"],"articleSection":["Company","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76665#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76665","url":"https:\/\/flcube.com\/?p=76665","name":"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76665#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76665#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2605.webp","datePublished":"2026-08-26T04:51:26+00:00","dateModified":"2026-08-26T04:51:27+00:00","description":"WuXi Biologics (HKG: 2269) announced its interim results for the six months ended 30 June 2026, reporting revenue of RMB 11.8 billion, up 18.4% year\u2011on\u2011year, driven by strong demand for new IND projects, continuous progression of projects into late\u2011stage development, and growing commercial manufacturing programs. The company achieved positive free cash flow of RMB 1.5 billion in the first half \u2014 its fifth consecutive year of positive free cash flow in H1.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76665#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76665"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76665#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2605.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2605.webp","width":1080,"height":608,"caption":"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76665#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2605.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76665"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76665\/revisions"}],"predecessor-version":[{"id":76672,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76665\/revisions\/76672"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76671"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}